UBS Group AG Lowers Holdings in AngioDynamics, Inc. $ANGO

UBS Group AG reduced its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 33.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 730,078 shares of the medical instruments supplier’s stock after selling 372,410 shares during the quarter. UBS Group AG’s holdings in AngioDynamics were worth $9,374,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in ANGO. Farther Finance Advisors LLC increased its stake in AngioDynamics by 146.4% in the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 1,199 shares during the last quarter. State of Wyoming increased its position in shares of AngioDynamics by 53.6% during the 3rd quarter. State of Wyoming now owns 4,749 shares of the medical instruments supplier’s stock valued at $53,000 after purchasing an additional 1,658 shares during the last quarter. State of Alaska Department of Revenue bought a new position in shares of AngioDynamics during the 3rd quarter valued at approximately $25,000. Washington Trust Advisors Inc. bought a new position in shares of AngioDynamics during the 3rd quarter valued at approximately $27,000. Finally, Rhumbline Advisers increased its position in shares of AngioDynamics by 4.3% during the 2nd quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock valued at $608,000 after purchasing an additional 2,510 shares during the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Trading Down 2.4%

Shares of ANGO stock opened at $10.77 on Friday. AngioDynamics, Inc. has a twelve month low of $8.36 and a twelve month high of $13.99. The stock has a market capitalization of $445.02 million, a price-to-earnings ratio of -14.36 and a beta of 0.37. The stock has a fifty day simple moving average of $10.75 and a two-hundred day simple moving average of $11.43.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Thursday, April 2nd. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative return on equity of 4.66% and a negative net margin of 10.01%.The business had revenue of $78.42 million during the quarter, compared to analysts’ expectations of $76.77 million. Research analysts predict that AngioDynamics, Inc. will post -0.19 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Zacks Research downgraded AngioDynamics from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 30th. Canaccord Genuity Group cut their target price on AngioDynamics from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Monday, April 6th. Freedom Capital raised AngioDynamics to a “strong-buy” rating in a research report on Monday, April 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of AngioDynamics in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $18.67.

AngioDynamics Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.